Search company, investor...

Stratos Genomics


Acquired | Acquired

Total Raised


About Stratos Genomics

Stratos Genomics is a biotechnology company that develops genome sequencing through the Sequencing by Expansion (SBX) method, a single-molecule detection process that circumvents the limitations of competing technologies. On June 1st, 2020 Stratos Genomics was acquired by Roche. The terms of the transaction were not disclosed.

Headquarters Location

World Trade Center East 2211 Elliott Ave. Suite #210

Seattle, Washington, 98121,

United States


Missing: Stratos Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stratos Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Stratos Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stratos Genomics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Stratos Genomics Patents

Stratos Genomics has filed 38 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA, Genetics, Biotechnology, Nucleotides


Application Date


Grant Date



Related Topics

Molecular biology, DNA, Genetics, Biotechnology, Nucleotides



Latest Stratos Genomics News

08:30 ET Global Long Read Sequencing Market Report to 2030 - Featuring MicrobesNG, NextOmics, Quantapore, Stratos Genomics and T...

Jan 4, 2023

News provided by Share this article Share this article The global long read sequencing market size is expected to reach USD 4.40 billion by 2030 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. Innovations and advancements by a key player in technologies to summit the mandate posed by the market are propelling the growth of the long-read sequencing market. Several research studies are arising which are supposed to make a modest rise for producers to create new and advanced technologies and contribute to various opportunities in long-read sequencing. The main application, such as peeling off the need to cut up and then amplify DNA which is generally required in other DNA sequencing techniques, contributes to the growth. Utilization of long-read sequencing for inventions of vaccines and medicines required for the Covid-19 virus has driven the long-read sequencing market, impacting the positive growth of the Covid -19 pandemic. An increasing number of mandatory Covid-19 testing according to rules and regulations increased the vaccine requirement leading to the development of the long-read sequencing market. Market Dynamics Long Read Sequencing Market Report Highlights The single-molecule real-time sequencing account for the largest market and is also expected to grow fastest over the forecast due to its longer read length and low systematic bias achieving high consensus accuracy. The long-read sequencing market is categorized as instruments, consumables, and services based on product. The consumables segment accounts for the largest market share in 2021. As in sequencing, it utilizes SMRT cells and SMRT sequencing reagents required for on-instrument sequencing improving software and computational equipment. Based on the application, the cancer segment accounted for the largest market share and is supposed to be the fastest growing segment over the forecast period. SMART sequencing is being used in research of hepatitis C virus, hepatitis B virus, HIV, influenza, and other disease-causing microbes. Advancements in data analysis tools and significant players expanding their market presence are anticipated for the market's growth. The sequencing segment accounts for the most critical long-read sequencing market share. Utilization of sequence analysis method in research, on-site bioinformatics classes offered by universities, and academic workshops have increased, increasing the growth of the long-read sequencing market. There is a rapid increase in genomic procedures for clinical and academic use in the U.S. in North America, increasing the market share for this region. The Asia Pacific is anticipated for the fastest growing area for the long-read sequencing market. The publisher has segmented the long read sequencing market report based on, technology, product, application, work-flow, end-uses, and regions: Long Read Sequencing, Technology Outlook (Revenue - USD Billion, 2018 - 2030) Single-Molecule real-time sequencing Instruments Identification and fine mapping of structural variation Tandem repeat sequencing Pre-sequencing Academic research North America Genome Transcriptome Facility of Bordeaux Institute of Integrative Biology of the Cell (I2BC) MicrobesNG Quantapore Inc.

Stratos Genomics Frequently Asked Questions (FAQ)

  • Where is Stratos Genomics's headquarters?

    Stratos Genomics's headquarters is located at World Trade Center East, Seattle.

  • What is Stratos Genomics's latest funding round?

    Stratos Genomics's latest funding round is Acquired.

  • How much did Stratos Genomics raise?

    Stratos Genomics raised a total of $53.2M.

  • Who are the investors of Stratos Genomics?

    Investors of Stratos Genomics include Roche Holding, Fisk Ventures, Roche Venture Fund, SV Health Investors and Stratos Group.

  • Who are Stratos Genomics's competitors?

    Competitors of Stratos Genomics include Sequentia Biotech.

Compare Stratos Genomics to Competitors


ACGT develops genomics-based solutions that increase productivity and enhance value creation from the oil palm and other oil crops. It is based in Kuala Lumpur, Malaysia.

Omixon Logo

Omixon is a global molecular diagnostics company that commercializes technologies for clinical and research laboratories. Omixon's flagship product, Holotype HLA, is an NGS-based HLA genotyping product that delivers high-resolution HLA genotyping. Omixon's research software, HLA Explore, analyzes data from any sequencing technology and determines HLA genotypes from whole exome/genome sequencing experiments.

Aperiomics Logo

Aperiomics identifies bacteria, viruses, fungi, and parasites through Deep Shotgun Metagenomic Sequencing, using its database of microbes. The company helps doctors and their patients identify the causes of infections that other tests cannot identify, thus streamlining the path to a positive clinical outcome.

Viome Logo

Viome develops technology that offers visibility into the ecosystem living inside people. It blends readings from blood, urine, saliva, and stool samples to develop profiles of biochemistry, as well as the microbes in the digestive system. The company feeds this profile into a smartphone app to offer personalized recommendations for diet and lifestyle. Viome was founded in 2016 and is based in Bellevue, Washington.

Genestack Logo

Genestack provides customers with multi-omics data management and integration software. It is based in Cambridge, England.

Sequentia Biotech

Sequentia Biotech is a bioinformatics company that transforms omics data into knowledge. The company offers bioinformatics cloud softwares, custom softwares and bioinformatics consulting services for healthcare, pharma, agriculture, industry and the environment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.